» Articles » PMID: 6743468

The Effects on Left Ventricular Performance of Nifedipine and Verapamil in Exercise-induced Angina Pectoris

Overview
Specialty Pharmacology
Date 1984 Jun 1
PMID 6743468
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The differences between slow calcium blocking agents with respect to effects on heart rate, myocardial contractility and atrioventricular conducting time are well described; the relevance of such differences to the treatment of patients with impaired left ventricular function due to coronary heart disease is uncertain. The haemodynamic effects of equivalent hypotensive doses of nifedipine and verapamil were therefore compared in 20 patients with severe angina pectoris associated with angiographically documented coronary artery disease. The plasma concentrations of nifedipine (mean 57 +/- 19; range 27-77 ng/ml) and verapamil (mean 147 +/- 14; range 117-260 ng/ml) at the time of the haemodynamic measurements were of an order usually associated with substantial pharmacodynamic activity. Sitting at rest nifedipine resulted in reduction in systemic arterial pressure (P less than 0.05) and vascular resistance (P less than 0.01); both the heart rate (P less than 0.01) and cardiac output (P less than 0.05) increased without any significant change in the left heart filling pressure. In contrast, verapamil, which similarly reduced systemic blood pressure (P less than 0.05) and vascular resistance (P less than 0.01), increased cardiac output (P less than 0.05) and left heart filling pressure (P less than 0.05) without any change in heart rate. During upright bicycle exercise both drugs attenuated the angina induced in all subjects during the control exercise period. Despite reductions in systemic blood pressure and vascular resistance the cardiac output was unaltered on either drug at the same workload as in the control assessment. The reduction in exercise blood pressure following nifedipine induced a reflex tachycardia; this was not present, despite the similar hypotensive action, after verapamil.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease.

Brogden R, Benfield P Drugs. 1996; 51(5):792-819.

PMID: 8861548 DOI: 10.2165/00003495-199651050-00007.


Pharmacokinetic, haemodynamic and radionuclide studies with nicardipine in coronary artery disease.

Silke B, Graham D, Verma S, Reynolds G, Frais M, Finlayson J Eur J Clin Pharmacol. 1986; 29(6):651-7.

PMID: 3709609 DOI: 10.1007/BF00615954.


Nifedipine. Relationship between pharmacokinetics and pharmacodynamics.

Kleinbloesem C, van Brummelen P, Breimer D Clin Pharmacokinet. 1987; 12(1):12-29.

PMID: 3545614 DOI: 10.2165/00003088-198712010-00002.


The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease. A review.

Soward A, Vanhaleweyk G, Serruys P Drugs. 1986; 32(1):66-101.

PMID: 2874975 DOI: 10.2165/00003495-198632010-00004.


Effects of nicardipine on cardiac volume at rest and during exercise-induced angina.

Silke B, Verma S, Frais M, Hafizullah M, Taylor S Br J Clin Pharmacol. 1985; 20 Suppl 1:169S-176S.

PMID: 2862901 PMC: 1400779. DOI: 10.1111/j.1365-2125.1985.tb05161.x.


References
1.
Coltart J, Alderman E, Robison S, Harrison D . Effect of propranolol on left ventricular function, segmental wall motion, and diastolic pressure-volume relation in man. Br Heart J. 1975; 37(4):357-64. PMC: 483877. DOI: 10.1136/hrt.37.4.357. View

2.
McALLISTER R, Howell S . Fluorometric assay of verapamil in biological fluids and tissues. J Pharm Sci. 1976; 65(3):431-2. DOI: 10.1002/jps.2600650330. View

3.
FLECKENSTEIN A . Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 1977; 17:149-66. DOI: 10.1146/annurev.pa.17.040177.001053. View

4.
Singh B, Roche A . Effects of intravenous verapamil on hemodynamics in patients with heart disease. Am Heart J. 1977; 94(5):593-9. DOI: 10.1016/s0002-8703(77)80128-2. View

5.
Ferlinz J, Easthope J, Aronow W . Effects of verapamil on myocardial performance in coronary disease. Circulation. 1979; 59(2):313-9. DOI: 10.1161/01.cir.59.2.313. View